SIREN : 775576002
SOPHARTEX is a French company founded 56 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in VERNOUILLET (28500), this company of category ETI shows in 2023 a revenue of 43.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 43 815 232 € | 42 471 539 € | 33 948 491 € | 36 742 180 € | 39 626 392 € | 33 749 331 € | 37 660 750 € | 41 579 829 € |
| Net income | -2 588 402 € | -1 227 153 € | -3 425 125 € | -2 157 354 € | -2 496 618 € | -1 388 666 € | -169 778 € | 667 960 € |
| EBITDA | -3 714 003 € | -117 501 € | -3 312 446 € | -1 627 793 € | -1 354 066 € | -2 106 874 € | -111 590 € | 1 548 891 € |
| Net margin | -5.9% | -2.9% | -10.1% | -5.9% | -6.3% | -4.1% | -0.5% | 1.6% |
In 2023, SOPHARTEX achieves revenue of 43.8 M€. Revenue is growing positively over 8 years (CAGR: +0.8%). Vs 2022: +3%. After deducting consumption (14.0 M€), gross margin stands at 29.8 M€, i.e. a rate of 68%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -3.7 M€, representing -8.5% of revenue. Warning negative scissor effect: despite revenue change (+3%), EBITDA varies by -3061%, reducing margin by 8.2 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -2.6 M€ (-5.9% of revenue), which will impact equity.
43 815 232 €
29 771 905 €
-3 714 003 €
-5 794 102 €
-2 588 402 €
-8.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -3%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
0.0%
-3.06%
-10.778%
0.0
18.3%
In 2023, the debt ratio of SOPHARTEX (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2023, the financial autonomy of SOPHARTEX (-3.1%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2023, the repayment capacity of SOPHARTEX (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 66.49. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
66.488
-32.001
In 2023, the liquidity ratio of SOPHARTEX (66.49) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2023, the interest coverage of SOPHARTEX (-32.0x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 37 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 75 days. Excellent situation: suppliers finance 38 days of the operating cycle (retail model). Inventory turnover is 83 days (= Average inventory / Cost of goods x 360). WCR is negative (-90 days): operations structurally generate cash. Notable WCR improvement over the period (-969%), freeing up cash.
-11 000 690 €
37 j
75 j
83 j
-90 j
Compare SOPHARTEX with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of SOPHARTEX in 2023 is 43.8 M€.
SOPHARTEX recorded a net loss in 2023.
The headquarters of SOPHARTEX is located in VERNOUILLET (28500), in the department Eure-et-Loir.
The tax return of SOPHARTEX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SOPHARTEX operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.